@article{Griesel2021,
abstract = {Dolutegravir, a second-generation integrase strand transfer inhibitor (InSTI), is replacing efavirenz as first-line antiretroviral therapy (ART) in low middle-income countries (LMICs). Tuberculosis remains the leading cause of HIV-related morbidity and mortality in LMICs. Rifampicin is a key agent in the treatment of tuberculosis but induces genes involved in dolutegravir metabolism and efflux. The resulting drug-drug interaction (DDI) reduces the exposure of dolutegravir. However, this can be overcome by supplying a supplemental dose of 50 mg dolutegravir 12 hours after the standard daily dose, which is difficult to implement in LMICs.},
author = {Griesel, Rulan and Hill, Andrew and Meintjes, Graeme A and Maartens, Gary},
doi = {10.12688/wellcomeopenres.16473.1},
file = {:C$\backslash$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Griesel et al. - 2021 - Standard versus double dose dolutegravir in patients with HIV-associated tuberculosis a phase 2 non-comparative.pdf:pdf},
issn = {2398-502X},
journal = {Wellcome Open Research},
keywords = {Dolutegravir,OA,drug-drug interaction,fund{\_}ack,protocol,rifampicin,tuberculosis},
mendeley-tags = {OA,fund{\_}ack,protocol},
month = {jan},
pages = {1},
pmid = {33954265},
publisher = {F1000 Research Limited},
title = {{Standard versus double dose dolutegravir in patients with HIV-associated tuberculosis: a phase 2 non-comparative randomised controlled (RADIANT-TB) trial [version 1; peer review: 2 approved]}},
url = {https://wellcomeopenresearch.org/articles/6-1/v1},
volume = {6},
year = {2021}
}

{"_id":"73CZakrNBKPzcx597","bibbaseid":"griesel-hill-meintjes-maartens-standardversusdoubledosedolutegravirinpatientswithhivassociatedtuberculosisaphase2noncomparativerandomisedcontrolledradianttbtrialversion1peerreview2approved-2021","author_short":["Griesel, R.","Hill, A.","Meintjes, G. A","Maartens, G."],"bibdata":{"bibtype":"article","type":"article","abstract":"Dolutegravir, a second-generation integrase strand transfer inhibitor (InSTI), is replacing efavirenz as first-line antiretroviral therapy (ART) in low middle-income countries (LMICs). Tuberculosis remains the leading cause of HIV-related morbidity and mortality in LMICs. Rifampicin is a key agent in the treatment of tuberculosis but induces genes involved in dolutegravir metabolism and efflux. The resulting drug-drug interaction (DDI) reduces the exposure of dolutegravir. However, this can be overcome by supplying a supplemental dose of 50 mg dolutegravir 12 hours after the standard daily dose, which is difficult to implement in LMICs.","author":[{"propositions":[],"lastnames":["Griesel"],"firstnames":["Rulan"],"suffixes":[]},{"propositions":[],"lastnames":["Hill"],"firstnames":["Andrew"],"suffixes":[]},{"propositions":[],"lastnames":["Meintjes"],"firstnames":["Graeme","A"],"suffixes":[]},{"propositions":[],"lastnames":["Maartens"],"firstnames":["Gary"],"suffixes":[]}],"doi":"10.12688/wellcomeopenres.16473.1","file":":C$\\$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Griesel et al. - 2021 - Standard versus double dose dolutegravir in patients with HIV-associated tuberculosis a phase 2 non-comparative.pdf:pdf","issn":"2398-502X","journal":"Wellcome Open Research","keywords":"Dolutegravir,OA,drug-drug interaction,fund_ack,protocol,rifampicin,tuberculosis","mendeley-tags":"OA,fund_ack,protocol","month":"jan","pages":"1","pmid":"33954265","publisher":"F1000 Research Limited","title":"Standard versus double dose dolutegravir in patients with HIV-associated tuberculosis: a phase 2 non-comparative randomised controlled (RADIANT-TB) trial [version 1; peer review: 2 approved]","url":"https://wellcomeopenresearch.org/articles/6-1/v1","volume":"6","year":"2021","bibtex":"@article{Griesel2021,\r\nabstract = {Dolutegravir, a second-generation integrase strand transfer inhibitor (InSTI), is replacing efavirenz as first-line antiretroviral therapy (ART) in low middle-income countries (LMICs). Tuberculosis remains the leading cause of HIV-related morbidity and mortality in LMICs. Rifampicin is a key agent in the treatment of tuberculosis but induces genes involved in dolutegravir metabolism and efflux. The resulting drug-drug interaction (DDI) reduces the exposure of dolutegravir. However, this can be overcome by supplying a supplemental dose of 50 mg dolutegravir 12 hours after the standard daily dose, which is difficult to implement in LMICs.},\r\nauthor = {Griesel, Rulan and Hill, Andrew and Meintjes, Graeme A and Maartens, Gary},\r\ndoi = {10.12688/wellcomeopenres.16473.1},\r\nfile = {:C$\\backslash$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Griesel et al. - 2021 - Standard versus double dose dolutegravir in patients with HIV-associated tuberculosis a phase 2 non-comparative.pdf:pdf},\r\nissn = {2398-502X},\r\njournal = {Wellcome Open Research},\r\nkeywords = {Dolutegravir,OA,drug-drug interaction,fund{\\_}ack,protocol,rifampicin,tuberculosis},\r\nmendeley-tags = {OA,fund{\\_}ack,protocol},\r\nmonth = {jan},\r\npages = {1},\r\npmid = {33954265},\r\npublisher = {F1000 Research Limited},\r\ntitle = {{Standard versus double dose dolutegravir in patients with HIV-associated tuberculosis: a phase 2 non-comparative randomised controlled (RADIANT-TB) trial [version 1; peer review: 2 approved]}},\r\nurl = {https://wellcomeopenresearch.org/articles/6-1/v1},\r\nvolume = {6},\r\nyear = {2021}\r\n}\r\n","author_short":["Griesel, R.","Hill, A.","Meintjes, G. A","Maartens, G."],"key":"Griesel2021","id":"Griesel2021","bibbaseid":"griesel-hill-meintjes-maartens-standardversusdoubledosedolutegravirinpatientswithhivassociatedtuberculosisaphase2noncomparativerandomisedcontrolledradianttbtrialversion1peerreview2approved-2021","role":"author","urls":{"Paper":"https://wellcomeopenresearch.org/articles/6-1/v1"},"keyword":["Dolutegravir","OA","drug-drug interaction","fund_ack","protocol","rifampicin","tuberculosis"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://drive.google.com/uc?export=download&id=1-JLqZ7RwZ3VC2d6ErLGHAtOeMRS_7GCz","dataSources":["Krmt6gt9ktB2s6ARh"],"keywords":["dolutegravir","oa","drug-drug interaction","fund_ack","protocol","rifampicin","tuberculosis"],"search_terms":["standard","versus","double","dose","dolutegravir","patients","hiv","associated","tuberculosis","phase","non","comparative","randomised","controlled","radiant","trial","version","peer","review","approved","griesel","hill","meintjes","maartens"],"title":"Standard versus double dose dolutegravir in patients with HIV-associated tuberculosis: a phase 2 non-comparative randomised controlled (RADIANT-TB) trial [version 1; peer review: 2 approved]","year":2021}